{
    "name": "memantine",
    "comment": "Rx",
    "other_names": [
        "Namenda XR",
        "Namenda"
    ],
    "classes": [
        "NMDA Antagonists"
    ],
    "source": "https://reference.medscape.com/drug/namenda-xr-memantine-343063",
    "pregnancy": {
        "common": [
            "There are no adequate data on developmental risk associated with use; adverse developmental effects (decreased body weight, and skeletal ossification) observed in offspring of rats during pregnancy at doses associated with minimal maternal toxicity; doses are higher than used in humans at maximum recommended daily dose"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Oral administration to rats during period of organogenesis resulted in decreased skeletal ossification in fetuses at highest dose tested; the higher no-effect dose (6 mg/kg/day) was approximately 3 times MRHD on a mg/m² basis",
                    "Oral administration of memantine to rabbits during period of organogenesis resulted in no adverse developmental effects; highest dose tested was approximately 30 times the MRHD on a mg/m² basis",
                    "Oral administration to rats from late gestation throughout lactation to weaning, resulted in decreased pup weights at highest dose tested; the higher no-effect dose (6 mg/kg/day) is approximately 3 times the MRHD on a mg/ m² basis"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of drug in human milk, effects on breastfed infant, or on milk production",
            "Developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to memantine or components of the formulation"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Not evaluated in patients with seizure disorder; seizures occurred in 0.2% of patients",
                "Conditions that raise urine pH may decrease urinary elimination and increase plasma levels of memantine",
                "Use caution in cardiovascular disease, seizure disorder, ophthalmic disease, hepatic and/or renal impairment"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "dextromethorphan",
            "description": {
                "common": "memantine, dextromethorphan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ketamine",
            "description": {
                "common": "memantine, ketamine.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tafenoquine",
            "description": {
                "common": "tafenoquine will increase the level or effect of memantine by  Other (see comment). Avoid or Use Alternate Drug. Tafenoquine inhibits organic cation transporter-2 (OCT2) and multidrug and toxin extrusion (MATE) transporters in vitro. Avoid coadministration with OCT2 or MATE substrates. If coadministration cannot be avoided, monitor for substrate-related toxicities and consider dosage reduction if needed based on product labeling of the coadministered drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trilaciclib",
            "description": {
                "common": "trilaciclib will decrease the level or effect of memantine by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of memantine by  passive renal tubular reabsorption - basic urine. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aluminum hydroxide",
            "description": {
                "common": "aluminum hydroxide will increase the level or effect of memantine by  passive renal tubular reabsorption - basic urine. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amantadine",
            "description": {
                "common": "memantine, amantadine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Combination may lead to additive adverse effects. If coadministration cannot be avoided, monitor for increased adverse effects such as agitation, dizziness and other CNS events."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiodarone",
            "description": {
                "common": "amiodarone will increase the level or effect of memantine by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium carbonate",
            "description": {
                "common": "calcium carbonate will increase the level or effect of memantine by  passive renal tubular reabsorption - basic urine. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cimetidine",
            "description": {
                "common": "cimetidine will increase the level or effect of memantine by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "digoxin will increase the level or effect of memantine by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dofetilide",
            "description": {
                "common": "dofetilide will increase the level or effect of memantine by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erdafitinib",
            "description": {
                "common": "memantine increases levels of erdafitinib by decreasing renal clearance. Modify Therapy/Monitor Closely. Consider alternatives that are not OCT2 substrates or consider reducing the dose of OCT2 substrates based on tolerability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "procainamide",
            "description": {
                "common": "memantine will increase the level or effect of procainamide by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinidine",
            "description": {
                "common": "quinidine will increase the level or effect of memantine by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium bicarbonate",
            "description": {
                "common": "sodium bicarbonate will increase the level or effect of memantine by  passive renal tubular reabsorption - basic urine. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium citrate/citric acid",
            "description": {
                "common": "sodium citrate/citric acid will increase the level or effect of memantine by  passive renal tubular reabsorption - basic urine. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium lactate",
            "description": {
                "common": "sodium lactate will increase the level or effect of memantine by  passive renal tubular reabsorption - basic urine. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenofovir DF",
            "description": {
                "common": "tenofovir DF increases levels of memantine by decreasing renal clearance. Use Caution/Monitor. Potential for increased toxicity. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vandetanib",
            "description": {
                "common": "vandetanib increases levels of memantine by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Vandetanib inhibits the uptake of substrates of organic cation transporter type 2 (OCT2)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of memantine by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "isavuconazonium sulfate will increase the level or effect of memantine by  Other (see comment). Minor/Significance Unknown. Isavuconazonium sulfate, an OCT2 inhibitor, may increase the effects or levels of OCT2 substrates."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metformin",
            "description": {
                "common": "memantine will increase the level or effect of metformin by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methyclothiazide",
            "description": {
                "common": "methyclothiazide will increase the level or effect of memantine by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "midodrine",
            "description": {
                "common": "memantine will increase the level or effect of midodrine by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ofloxacin",
            "description": {
                "common": "memantine will increase the level or effect of ofloxacin by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pramipexole",
            "description": {
                "common": "memantine will increase the level or effect of pramipexole by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "quinine",
            "description": {
                "common": "memantine will increase the level or effect of quinine by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sulfamethoxazole",
            "description": {
                "common": "sulfamethoxazole will increase the level or effect of memantine by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "triamterene",
            "description": {
                "common": "memantine will increase the level or effect of triamterene by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trimethoprim",
            "description": {
                "common": "memantine will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "verapamil",
            "description": {
                "common": "memantine will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Dizziness",
            "percent": "7"
        },
        {
            "name": "Confusion",
            "percent": "6"
        },
        {
            "name": "Headache",
            "percent": "6"
        },
        {
            "name": "Constipation",
            "percent": "5"
        },
        {
            "name": "Cough",
            "percent": "4"
        },
        {
            "name": "Hypertension",
            "percent": "4"
        },
        {
            "name": "Backache",
            "percent": "3"
        },
        {
            "name": "Pain",
            "percent": "3"
        },
        {
            "name": "Somnolence",
            "percent": "3"
        },
        {
            "name": "Syncope",
            "percent": "3"
        },
        {
            "name": "Vomiting",
            "percent": "3"
        },
        {
            "name": "Dyspnea",
            "percent": "2"
        },
        {
            "name": "Fatigue",
            "percent": "2"
        },
        {
            "name": "Acute renal failure",
            "percent": null
        },
        {
            "name": "Cerebral infarction",
            "percent": null
        },
        {
            "name": "Cerebrovascular accident",
            "percent": null
        },
        {
            "name": "Deep venous thrombosis",
            "percent": null
        },
        {
            "name": "Hepatitis",
            "percent": null
        },
        {
            "name": "liver failure",
            "percent": null
        },
        {
            "name": "Intracranial hemorrhage",
            "percent": null
        },
        {
            "name": "Neuroleptic malignant syndrome",
            "percent": null
        },
        {
            "name": "Seizure",
            "percent": null
        },
        {
            "name": "including grand mal",
            "percent": null
        },
        {
            "name": "Stevens",
            "percent": null
        },
        {
            "name": "Johnson syndrome",
            "percent": null
        },
        {
            "name": "Transient ischemic attack",
            "percent": null
        },
        {
            "name": "Blood and lymphatic system disorders",
            "percent": null
        },
        {
            "name": "Agranulocytosis",
            "percent": null
        },
        {
            "name": "leukopenia",
            "percent": null
        },
        {
            "name": "including neutropenia",
            "percent": null
        },
        {
            "name": "pancytopenia",
            "percent": null
        },
        {
            "name": "thrombocytopenia",
            "percent": null
        },
        {
            "name": "thrombotic thrombocytopenic purpura",
            "percent": null
        },
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "Cardiac failure congestive",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Pancreatitis",
            "percent": null
        },
        {
            "name": "Hepatobiliary disorders",
            "percent": null
        },
        {
            "name": "Hepatitis",
            "percent": null
        },
        {
            "name": "Psychiatric disorders",
            "percent": null
        },
        {
            "name": "Suicidal ideation",
            "percent": null
        },
        {
            "name": "Renal and urinary disorders",
            "percent": null
        },
        {
            "name": "Acute renal failure",
            "percent": null
        },
        {
            "name": "including increased creatinine and renal insufficiency",
            "percent": null
        },
        {
            "name": "Skin disorders",
            "percent": null
        },
        {
            "name": "Stevens Johnson syndrome",
            "percent": null
        }
    ]
}